Antitumor response of genetically engineered IL-2 expression to human esophageal carcinoma cells in mature T cell-defective condition.

  • Authors:
    • H Matsubara
    • Y Koide
    • M Sugaya
    • Y Gunji
    • T Asano
    • T Ochiai
    • K Takegana
    • S Sakiyama
    • M Tagawa
  • View Affiliations

  • Published online on: December 1, 1998     https://doi.org/10.3892/ijo.13.6.1217
  • Pages: 1217-1239
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We examined whether antitumor effect could be produced by retrovirally expressed human interleukin-2 (hIL-2) gene in human esophageal cancer cells (T.Tn) using immunocompromised nude mice. Loss of tumorigenicity of hIL-2-producing T.Tn (T.Tn/hIL-2) cells inoculated subcutaneously was observed in contrast to continuous tumor growth of wild-type cells, although in vitro proliferation of T.Tn/hIL-2 cells remained the same as that of wild-type cells. The antitumor effect was also evidenced by the injection of T.Tn/hIL-2 cells into established tumors of wild-type cells. The injection significantly retarded the subsequent growth of wild-type tumors. Histological examination of regressing T.Tn/hIL-2 cells revealed necrotic areas and infiltration of several types of inflammatory cells. Treatment of nude mice with anti-asialoGM1 antibody did not influence the IL-2-mediated tumor rejection. Vaccination of nude mice with irradiated T.Tn/hIL-2 cells whose secretion of hIL-2 in amount was comparable to that of unirradiated cells did not develop protective immunity. Taken together, the antitumor effect achieved in nude mice by the inoculation of T.Tn/hIL-2 cells is mediated by non-T non-natural killer cells.

Related Articles

Journal Cover

Dec 1998
Volume 13 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Matsubara H, Koide Y, Sugaya M, Gunji Y, Asano T, Ochiai T, Takegana K, Sakiyama S and Tagawa M: Antitumor response of genetically engineered IL-2 expression to human esophageal carcinoma cells in mature T cell-defective condition.. Int J Oncol 13: 1217-1239, 1998.
APA
Matsubara, H., Koide, Y., Sugaya, M., Gunji, Y., Asano, T., Ochiai, T. ... Tagawa, M. (1998). Antitumor response of genetically engineered IL-2 expression to human esophageal carcinoma cells in mature T cell-defective condition.. International Journal of Oncology, 13, 1217-1239. https://doi.org/10.3892/ijo.13.6.1217
MLA
Matsubara, H., Koide, Y., Sugaya, M., Gunji, Y., Asano, T., Ochiai, T., Takegana, K., Sakiyama, S., Tagawa, M."Antitumor response of genetically engineered IL-2 expression to human esophageal carcinoma cells in mature T cell-defective condition.". International Journal of Oncology 13.6 (1998): 1217-1239.
Chicago
Matsubara, H., Koide, Y., Sugaya, M., Gunji, Y., Asano, T., Ochiai, T., Takegana, K., Sakiyama, S., Tagawa, M."Antitumor response of genetically engineered IL-2 expression to human esophageal carcinoma cells in mature T cell-defective condition.". International Journal of Oncology 13, no. 6 (1998): 1217-1239. https://doi.org/10.3892/ijo.13.6.1217